JPRN-jRCT2080220672未知2 期
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Type 2 diabetes patients with HbA1c above 7.0% and below 10%
- •- Patients who are capable of giving informed consent
- •- Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner
排除标准
- •- Patients with type1 diabetes mellitus, patients with diabetes mellitus or impaired glucose tolerance (IGT) due to other specified mechanism or diseases, and patients with gestational diabetes mellitus
- •- Patients with a medical history of diabetes coma
- •- Patients with poorly-controlled hypertension
- •- Patients with heart failure
- •- Patients with a complication of active hepatitis or hepatic cirrhosis
- •- Patients undergoing treatment of glomeruler diseases other than diabetic nephropathy
- •- Patients with a history or complication of malignant tumor
研究者
相似试验
已完成
2 期
A Phase 2 Study of OPC-262 in Patients With Type 2 DiabetesDiabetes, Type 2NCT00857558Kyowa Kirin Co., Ltd.350
未知
3 期
A Phase 3 Study of OPC-262 in patients with type 2 diabetesPatients with type 2 diabetesJPRN-jRCT2080220920Otsuka Pharmaceutical Co., Ltd.100
未知
3 期
A long-term clinical study of OPC-262 in patients with type 2 diabetestype 2 diabetesJPRN-jRCT2080221847Otsuka Pharmaceutical Co., Ltd.175
已完成
3 期
Double blind, randomised, comparative, multicentre, parallel-group study design to evaluate the effects of Pioglitazone on cardiovascular risk markers in type 2 diabetes mellitusACTRN12608000534381Takeda Italia Farmaceutici S.p.A.100
未知
2 期
Phase II clinical study of TY-0201 in patients with chronic heart failureChronic heart failureJPRN-jRCT2080222593TOA EIYO LTD.40